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MaIn addition to aggressive lifestyle and nonlipid risk factor modiﬁcation, statin therapy improves cardiovascular disease
outcomes following acute coronary syndromes. Despite established beneﬁts of treatment, contemporary registries reveal
substantial underutilization of and nonadherence to statin therapy for secondary prevention. In randomized controlled
trials investigating statin therapy, including moderate-intensity statin plus ezetimibe therapy, rates of nonadherence are
reported in up to 40% of subjects. Durable strategies to address gaps in lipid lowering for secondary prevention are
essential to maximize reduction in cardiovascular disease risk. (J Am Coll Cardiol 2015;66:184–92) © 2015 by the
American College of Cardiology Foundation.L ipid lowering with 3-hydroxy-3-methyl-glu-taryl-CoA reductase inhibitor (statin) therapyis essential for secondary prevention after
acute coronary syndromes (ACS) in combination
with an antiplatelet agent, beta-blocker, angio-
tensin-converting enzyme inhibitor, or angiotensin
receptor antagonist, and intensive lifestyle and
risk factor modiﬁcations, including weight reduction
in overweight individuals, smoking cessation, and
aerobic exercise. Statin therapy lowers concentra-
tions of low-density lipoprotein-cholesterol (LDL-C)
and other apolipoprotein-B–containing lipoproteins,
reduces arterial inﬂammation, stabilizes the lipid
core, and promotes regression of atherosclerosis
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accrue within the ﬁrst 6 months after ACS (3,4).
Consequently, high-intensity statin therapy before
hospital discharge after ACS is a Class I, Level of Evi-
dence: A guideline-recommendation, irrespective of
baseline LDL-C level (5).
Despite these established beneﬁts, contemporary
registries reveal substantial underutilization of and
nonadherence to statin prescriptions for secondary
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AB BR E V I A T I O N S
AND ACRONYM S
ACS = acute coronary
syndrome(s)
CVD = cardiovascular disease
FDC = ﬁxed-dose combination
therapy
LDL-C = low-density-
lipoprotein cholesterol
MI = myocardial infarction
RCT = randomized controlled
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185discontinued the study medication prematurely (6).
Clinical practice registries demonstrate even higher
nonadherence rates. Other clinical trials and registries
have reported higher mortality rates following
discontinuation of statin therapy after ACS (2,7).
Suboptimal pharmacologic LDL-C lowering after ACS
can be attributed to statin underutilization (Table 1)
and to medication nonadherence (Tables 2 and 3).
UNDERUTILIZATION OF
STATIN THERAPY AFTER ACS:
CONTEMPORARY EVIDENCE
In a recent issue of the Journal, Maddox et al. (8)
used the National Cardiovascular Data Registry’s
PINNACLE (Practice Innovation and Clinical Excel-
lence) database to assess the effect of the 2013
American College of Cardiology/American Heart As-
sociation cholesterol guidelines (5) on current car-
diovascular practice in the United States. In the
cohort of 1,174,545 patients age 18 years or older,
1,029,633 (91.2%) were eligible for statins on the
basis of known atherosclerotic CVD. Among patients
with atherosclerotic CVD, 506,009 (49.9%) received
statin therapy only; 200,789 (20.0%) received both
statin and nonstatin therapies; 28,887 (2.9%)
received nonstatin therapy only; and 285,211 (27.9%)
patients did not receive any lipid-lowering medica-
tion. These ﬁndings suggest that a large number of
patients lack optimized lipid management. Similar
ﬁndings were reported in a recent analysis of sec-
ondary prevention in patients with a history of
myocardial infarction (MI) from the large National
Health and Nutrition Examination Survey (9).
Although statin use in the United States increased
over the past decade from 36% in 1999 to nearly 73%
in 2012 (p ¼ 0.04), opportunities exist to improve
risk reduction and lipid lowering for the 27% of pa-
tients who are not currently taking statin therapy
after ACS.
The statin dose prescribed after ACS is also a
concern. A separate publication in the Journal
examined a sample of Medicare beneﬁciaries who
were prescribed a statin at discharge following a
hospitalization for ACS from 2007 to 2009 (10). Only
27.0% of prescriptions ﬁlled were for a high-intensity
statin, which increased to only 35% within 365 days
from the discharge date. Among patients not taking
statins before admission, 23.1% were prescribed a
high-intensity statin at discharge. Only 9.4% of
patients treated with a low- to moderate-intensity
statin before admission were prescribed a high-
intensity statin at discharge. In contrast, 80.7% of
patients treated with a high-intensity statin beforeadmission were prescribed the high-intensity
dose at discharge.
Other registries have reported similar
ﬁndings. In the United States and Europe,
23% to 38% of patients hospitalized for MI are
prescribed maximal-intensity statin therapy
at discharge (11–13). An observational study of
6,748 patients at 31 U.S. hospitals enrolled in
both the PREMIER (Prospective Registry
Evaluating Myocardial Infarction: Events and
Recovery) and the TRIUMPH (Translational
Research Investigating Underlying disparities
in acute Myocardial infarction Patients’ Health status)
registries (11) found that although 88% of patients
were prescribed a statin at discharge after ACS,
only 1 in 3 were prescribed a statin at goal dose. The
TRIUMPH registry deﬁned the goal dose as achieving
>75% of maximal statin potency (approximately a
50% to 60% reduction in LDL-C), which included:
atorvastatin 40 to 80 mg, lovastatin 80 mg, pravas-
tatin 80 mg, rosuvastatin 20 to 40 mg, or simvastatin
80 mg daily.
These failures to prescribe statins or to maximize
statin intensity suggest a lack of knowledge regarding
the beneﬁts of high-dose statin therapy over moder-
ate- or low-dose statin therapy (14), as demonstrated
in clinical trials of ACS patients (3,15). For example, the
most important predictor of change to a high-intensity
statin was the dosage the patient received before the
ACS event (10), suggesting a continued treatment
focus on LDL-C levels, lack of knowledge regarding the
beneﬁts of high-intensity statins, or clinical inertia.
Underutilization of high-intensity statin diminished
progressively in the year after the ACS event. Frag-
mented care in inpatient and ambulatory settings and
poor communication between community-care pro-
viders and specialists may limit provider attention to
starting statin therapy or dose optimization. To
improve decision-making and statin utilization for
older patients with multiple comorbidities on several
medications, physicians may need alternative guide-
lines that address concerns for possible medication
interactions with statins (16). Nurse-managed pro-
tocols may provide another useful approach in
improving outpatient implementation of guideline-
directed measures and promoting adherence of pa-
tients with multiple medical comorbidities (17).
Shorter hospitalizations for acute MI over the
past decade permit less time for dose titration
before discharge. Moreover, current performance
measures credit providers for any dose of guideline-
recommended medication, even a low/moderate-
intensity statin (11). Although speciﬁc reasons for
statin nonprescription, such as prior intolerance, may
trial
TABLE 1 Underutilization of Statin Therapy for Secondary Prevention
First Author (Ref. #) Registry Years N
Statin
Prescribed Inclusion Criteria
Rosenson et al. (10) CMS 2006–2010 8,762 27%* Medicare beneﬁciaries 65–74 yrs of age who
ﬁlled a statin prescription after a CHD event
Maddox et al. (8) PINNACLE 2008–2012 1,029,633 72%† Adults with conﬁrmed ASCVD
Arnold et al. (11) TRIUMPH 2005–2008 4,271 91%†/23%‡ Adults hospitalized with ACS, discharged alive,
no contraindications to statin
Arnold et al. (12) PREMIER þ TRIUMPH 2003–2008 6,748 88%§/33%k Adults hospitalized with ACS, discharged alive
Javed et al. (13) GWTG 2005–2009 65,396 89%†/38%* Adults hospitalized with ACS, prescribed
lipid-lowering therapy at discharge
Ho et al. (32) KPCO CAD Registry 2000–2005 15,767 86%† Patients in CAD registry with prior MI, PCI,
or CABG
Ho et al. (51) PREMIER 2003–2004 2,498 80%† Adults hospitalized with ACS, discharged alive
*Intensive lipid-lowering therapy with atorvastatin 40 or 80 mg, rosuvastatin 20 or 40 mg, simvastatin 80 mg, or statin of any dose þ ezetimibe þ any statin therapy. †Any
statin therapy. ‡Maximally potent statin (rosuvastatin 20 to 40 mg or atorvastatin 80 mg) at hospital discharge. §Any statin therapy at hospital discharge. kStatin at $75% of
the target dose at hospital discharge.
ACS ¼ acute coronary syndrome(s), ASCVD ¼ atherosclerotic cardiovascular disease; CABG ¼ coronary artery bypass graft; CAD ¼ coronary artery disease; CHD ¼ congenital
heart disease; CMS ¼ Centers for Medicare and Medicaid Services; GWTG ¼ Get With The Guidelines; KPCO ¼ Kaiser-Permanente of Colorado; MI ¼myocardial infarction; PCI ¼
percutaneous coronary intervention; PINNACLE ¼ Practice Innovation And Clinical Excellence; PREMIER ¼ Prospective Registry Evaluating Myocardial Infarction: Events and
Recovery; TRIUMPH ¼ Translational Research Investigating Underlying disparities in acute Myocardial infarction Patients’ Health status.
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186account for some treatment gaps in quality of care
metrics at discharge, further studies are required to
understand and address deﬁciencies. Continued
monitoring of practice patterns will facilitate health
care delivery of optimal therapies for secondary pre-
vention (18).
NONADHERENCE TO STATIN THERAPY FOR
SECONDARY PREVENTION
IMPROVE-IT is the ﬁrst clinical outcomes trial to
show that statin therapy plus a nonstatin LDL-C–
lowering treatment reduces CVD in patients who
are at high risk of recurrent CVD events. Even in
this well-designed trial, 42% of subjects prematurely
discontinued the study therapy, likely reducing
the treatment effect in both arms and leading to
underestimation of the observed beneﬁt. The ave-
rage annualized rate of statin discontinuation in
IMPROVE-IT is similar to that in other large RCTs
of statin therapy for secondary prevention (Table 2).
The highest annual rates of statin discontinuation
were reported in the A to Z (Aggrastat to Zocor) (19)
and PROVE IT-TIMI 22 (Pravastatin or Atorvastatin
Evaluation and Infection Therapy–Thrombolysis In
Myocardial Infarction 22) (14) trials, with >30% of
patients discontinuing therapy over the course of
follow-up. In the majority (55%) of cases in the A to
Z trial, the study statin was discontinued due to
physician or patient preference, with adverse expe-
riences or events accounting for 28% of premature
discontinuation (19). In the PROVE IT-TIMI 22 study,
only 5.3% of patients discontinued the studyatorvastatin dose due to laboratory abnormalities or
side effects; the remainder stopped due to patient or
physician preference (14). In-depth focus on the
rationale for premature study drug discontinuation
in clinical trials, commonly ascribed to patient or
physician preference, may inform explanations for
statin discontinuation in routine clinical practice. In
large, real-world registries of patients with CHD,
adherence to statin therapy is even lower than in
clinical trials and can reach 50% at 1 year (Table 3).
In addition to statin underutilization, nonadherence
to lipid-lowering therapy for secondary prevention
remains an important obstacle to CVD event reduc-
tion (Central Illustration).
Adherence refers to the extent to which a pa-
tient’s medication-taking practice coincides with
prescribed medical recommendations (20). Although
many patient characteristics can affect statin efﬁ-
cacy, nonadherence is among the most important
determinants of outcome. Rasmussen et al. (21)
demonstrated that increasing levels of statin ad-
herence are inversely associated with LDL-C and
mortality after ACS. Only 50% to 60% of patients
remain adherent within 1 year of initiation, de-
clining to 30% to 40% at 2 years (22,23). Non-
adherence is multifactorial and is inﬂuenced by
demographic and socioeconomic factors, lifestyle
habits, time since last provider visit, adverse effects
of therapy, and complex medication regimens (24).
Nonadherence affects all guideline-directed medical
therapy, including LDL-C–lowering therapy. A mul-
timodality, systems-based, incentive approach may
be necessary to overcome these barriers.
TABLE 2 Rates of Statin Discontinuation in RCTs With Statins Including Patients With Prior ACS
Study (Ref. #) Year N Statin Studied
Discontinuation of
Statin Therapy
Follow-Up
Duration
Average Annual %
Discontinuation
IMPROVE-IT (6) 2014 18,144 Simvastatin 42% 72 months* 7.0%
SEARCH (52) 2010 12,064 Simvastatin 27% 80 months† 4.1%
IDEAL (53) 2005 8,888 Atorvastatin 14% 58 months* 2.9%
TNT (54) 2005 10,001 Atorvastatin 7%‡ 59 months* 1%‡
A to Z (19) 2004 4,497 Simvastatin 34% 24 months* 17.2%
PROVE IT-TIMI 22 (14) 2004 4,162 Atorvastatin 30% 24 months† 15.2%
HPS (55) 2002 20,536 Simvastatin 18% 60 months† 3.6%
LIPID (56) 1998 9,014 Pravastatin 19% 73 months† 3.1%
CARE (57) 1996 4,159 Pravastatin 6% 60 months* 1.2%
4S (58) 1994 4,444 Simvastatin 10% 65 months* 1.9%
*Median. †Mean. ‡Discontinuation due to treatment-related adverse events only. All-cause discontinuation was not reported.
4S ¼ Scandinavian Simvastatin Survival Study; ACS ¼ acute coronary syndrome(s); A to Z ¼ Aggrastat to Zocor; CARE ¼ Cholesterol and Recurrent Events; HPS ¼ Heart
Protection Study; IDEAL ¼ Incremental Decrease in End Points Through Aggressive Lipid Lowering; IMPROVE-IT ¼ IMProved Reduction of Outcomes: Vytorin Efﬁcacy
International Trial; LIPID ¼ Long-Term Intervention with Pravastatin in Ischaemic Disease; PROVE IT-TIMI 22 ¼ Pravastatin or Atorvastatin Evaluation and Infection Therapy–
Thrombolysis In Myocardial Infarction 22; RCT ¼ randomized controlled trial; SEARCH ¼ Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine;
TNT ¼ Treating to New Targets.
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187MEASURING ADHERENCE
Providers are currently not adept at recognizing
nonadherence (25). In qualitative studies, providers
did not inquire about adherence in one-third of pa-
tients with poor blood pressure control (26,27), sug-
gesting a need for broader recognition of the
importance of nonadherence to outcomes, which will
be increasingly linked to provider payment, posing
both new challenges and opportunities. Measuring
nonadherence is challenging, requiring integration of
health services at multiple levels. Currently, adher-
ence is inferred on the basis of pill counts, blister
packs, and patient questionnaires or self-reports,TABLE 3 Adherence to Statin Therapy for Secondary Prevention of C
First Author (Ref. #) Registry Years
Ho et al. (51) PREMIER 2003–20
Ho et al. (32) KPCO 2000–20
Muntner et al. (23) CMS Chronic Condition
Data Warehouse
2007–20
Yang et al. (59) Medicare Part D Enrollees 2005–20
Foody et al. (60) PharmMetrics Patient
Centric Database
2003–20
Ye et al. (61) MedStat MarketScan Commercial
Claims and Encounters
Database þ Medicare
Supplemental and Coordination
of Beneﬁt Database
2000–20
*Interview with medication review. †Proportion of days covered $80%. ‡Proportion of
Abbreviations as in Table 1.such as diaries. Questioning of patients during
provider visits or through questionnaires can be sus-
ceptible to misrepresentation and tend to over-
estimate adherence (25,26). Pill counts, another
common approach to assess medication adherence,
appear to be simple and objective. However, patients
can switch medicines between bottles and may have
an insufﬁcient or excess quantity of pills that can
inﬂuence accuracy (26,27). Despite these biases,
poorer adherence, as measured by these methods, has
been associated with adverse CVD events (24,27).
Electronic monitoring devices and event monitors
that record the timing and opening of bottles pro-
vide more reliable data on adherence dynamics overAD in Registry Databases
N
Statin
Adherence Inclusion Criteria Follow-Up (Yrs)
04 2,498 78.5%* Adults hospitalized with ACS, discharged
alive, no contraindications to statin
1
05 13,596 74%† Patients in Kaiser CAD registry with
prior MI, PCI, or CABG
4.1
09 2,695 63.8%‡ Medicare beneﬁciaries with CHD-related
hospitalization, ﬁlled prescriptions
for antihypertensive, initiation of
statin therapy within 90 days of
hospital discharge
1
06 962,877 53.6%† Medicare Part D enrollees with diabetes 0.5
05 11,331 50%§ Statin naïve adults with a prior cardiac
event and $1 prescription for
atorvastatin or simvastatin
0.75
02 5,548 61.4%k Patients who initiated statin treatment
within 6 months of hospitalization
for cardiovascular disease
1
days covered $50%. §Continuation without >60-day gap. kMedication possession ratio $80%.
CENTRAL ILLUSTRATION Lipid Lowering After ACS: Opportunities at Multiple Levels of Health Care Delivery to Address Challenges
in Provider Utilization of and Patient Adherence to Statin Therapy After ACS
HEALTH SYSTEM FACTORS PROVIDER BEHAVIOR PATIENT FACTORS
Challenges
• Limited access
to medical care
• Multiple providers 
• High copayments
and insurance 
coverage
• High drug costs
• Clinical inertia
Solutions
• Education/media 
campaign
• Coordination
of care
• Reduce or eliminate 
copayments
• Pill burden reduction 
with fixed dose 
combination therapy 
(polypill)
• Pharmacy refill 
tracking/reminders
• Automated
pill counters
Solutions
• Provider education
• Clinical decision 
support tools (EMR 
prescribing alerts)
• Adherence
to guidelines
• Participation in
quality improvement 
programs
• Team-based approach
• Dosing strategies
for patients with 
presumed statin 
intolerance
• Re-challenge with 
statin in patients with 
a history of myalgia
Challenges
• Demographics, 
socioeconomics
• Lack of patient 
education
• Co-morbid conditions
• Depression
(particularly post-ACS)
• Cognitive impairment
• Caregiver involvement
• Adverse reactions and 
intolerance to statins
• Polypharmacy
• Drug-drug interactions
• White coat adherence
Solutions
• Discharge counseling
• Patient education
• Smartphone reminder 
applications
• Pill burden reduction 
with fixed dose 
combination therapy 
(polypill)
• Once-daily 
medication dosing
• Patient outreach 
programs
• Caregiver
participation
• Cardiac
rehabilitation
Challenges
• Failure to prescribe
statin therapy
• Failure to maximally
intensify statins
• Failure to 
reintroduce
statins
• Time constraints
Optimal Statin Use After Acute Coronary Syndrome
Hirsh, B.J. et al. J Am Coll Cardiol. 2015; 66(2):184–92.
ACS ¼ acute coronary syndrome(s); EMR ¼ electronic medical record.
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188time and, therefore, greater insight into patients’
medication-taking behavior (28). Electronic medica-
tion packaging devices are also being tested to
improve monitoring of adherence. Although these
methods are used widely in research settings, there
is limited data supporting their validity in routine
clinical practice, and variability in the quality of
studies testing these devices complicates assess-
ments of their efﬁcacy (29). Other direct measures of
adherence, including measurements of medication
levels or metabolites, were effective in improving
blood pressure control for patients with resistant
hypertension (30); however, these methods are
currently too inconvenient and costly for routine
practice (24).
Clinical support tools may also be used to facilitate
assessment of adherence. Other measures strongly
associated with nonadherence include physiological
markers, such as visit-to-visit variability in LDL-C
(31). More recently, electronic pharmacy reﬁll data
have been utilized to monitor adherence; patients
with prescriptions ﬁlled $80% of the time are cate-
gorized as adherent (32). This approach is gaining
momentum, but requires that patients obtain pre-
scriptions within a closed pharmacy system. Reliablemeasurements and implementation of interventions
to improve adherence will require strong clinical care
partnerships between multiple providers, pharma-
cies, caregivers, and patients.
SOCIODEMOGRAPHICS AND
HEALTH SYSTEMS
Lower-income earners, black or Hispanic women,
those without access to a caregiver, and patients with
higher copayments are more likely to discontinue
statin treatment after MI (33). Several interventions
may improve adherence for these vulnerable pa-
tients. Health literacy interventions, including
instructional checklists, educational drug fact pam-
phlets, and national campaigns promoting disease
awareness, have illustrated the beneﬁts of treatment.
Providing information in the patient’s native lan-
guage may lessen the burden of poor health literacy.
Policy changes designed to overcome barriers to
care, such as elimination of out-of-pocket costs, the
use of generic rather than brand-name medications,
and full coverage for preventative medications after
MI, are cost-neutral with respect to overall health
care spending and have demonstrated improved
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189adherence (34,35). Other health system barriers to
optimal secondary prevention include access to pro-
vider appointments, continuity of care, prescription
of limited numbers of medication reﬁlls, and pro-
viders’ competing priorities for patients with multiple
medical comorbidities (18). Other patient-level bar-
riers to care include belief systems, varying expecta-
tions of treatment, forgetfulness, and lack of
noticeable beneﬁts of taking medications with
apparent side effects (36).
At an initial patient encounter, providers should
gather data on drug insurance coverage, social
support, and the role of the caregiver. The pro-
vider should assess the risk for medication non-
adherence, evaluate reasons for forgetfulness (when
applicable), and consider the expectation of the
treatment outcome most valued by the patient.
Because physician time constraints can make such
conversations impractical, team-based approaches
may be necessary. In addition to outpatient nurse-
management protocols, pharmacy outreach pro-
grams are effective in providing further education
on medications, monitoring, and reinforcing adher-
ence (31,37).
LIFESTYLE AND COMORBID CONDITIONS
Obesity, smoking, alcohol consumption, and the
presence of medical comorbidities are associated with
nonadherence to statin therapy in secondary pre-
vention (32). Providers, family caregivers, and health
care systems must facilitate and support behavioral
changes. Cardiac rehabilitation is an underutilized
intervention that demonstrates a signiﬁcant effect on
morbidity and mortality after MI, percutaneous cor-
onary intervention, or coronary artery bypass graft
(38). In addition to improved health beneﬁts through
enhanced physical activity and nutritional coun-
seling, participants demonstrate >30% improvement
in adherence to statin therapy (39).
Depression is an underappreciated predictor of
statin nonadherence in outpatients with CVD.
Recognition of the signs and symptoms of depression
and routine screening can provide important cli-
nical information to physicians at both initial and
subsequent visits (40). Psychosocial support and
behavioral tools can be valuable for integrating
medication adherence into daily life. Adherence may
be improved by communication with open-ended
questions and shared decision-making. Likewise,
adherence to cardiovascular medications has been
linked to faith in the provider, suggesting that the
quality of the patient-provider relationship may be an
important determinant (24).RECOGNIZING TEMPORAL PATTERNS
IN ADHERENCE
Patient adherence is greatest in the 5 days before and
after an appointment with a provider, and diminishes
signiﬁcantly thereafter; this is termed “white coat
adherence” (41). Adherence can be improved by
applying individualized surveillance through inter-
ventions including electronic medical prescription-
ﬁlling records and use of reminder trigger systems.
Currently, over 90% of the U.S. population owns a
mobile phone, and recent efforts have demonstrated
successful utilization of text messaging to understand
and improve adherence (42). Future trials that in-
corporate this technology in the study design are
likely to improve adherence.
The transition from the inpatient to the outpatient
setting is another crucial time period to monitor and
ensure adherence. A multimodal approach has been
effective. Ho et al. (43) randomized 253 patients dis-
charged after ACS from 4 centers to either a multi-
faceted intervention to improve adherence or usual
care. The intervention arm, combining education and
counseling at discharge with post-discharge commu-
nication with pharmacists and automated voice
messages, demonstrated a 15.4% increase in adher-
ence (89.3% vs. 72.9%; p ¼ 0.003) over the year
following discharge. Another approach improved
early adherence by programming an electronic med-
ical record–linked automated phone call reminder to
patients who did not ﬁll a statin prescription 1 to 2
weeks post-discharge (44).
ADVERSE EFFECTS OF
LIPID-LOWERING THERAPY
Statin intolerance and concerns regarding adverse
effects of statin therapy contribute to nonadherence.
Many patients may be reluctant to begin statin ther-
apy due to concern for developing adverse events. In
RCTs, statin therapy causes only a slight increase in
side effects compared with placebo. Statin intoler-
ance ranges from approximately 1% to 10% in RCTs, to
as high as 10% to 25% in observational studies (33,45).
Myalgia, the most common reason for discontinua-
tion, occurs with similar frequency in both placebo
and treatment arms (45,46). In a recent systematic
analysis on myalgia prevalence reported by 26 statin
clinical trials, Ganga et al. (45) found an average
incidence of 12.7% in patients treated with statins
compared with 12.4% in the placebo group (p ¼ 0.06),
suggesting that both patients and physicians over-
estimate the frequency of statin-associated myalgia.
However, clinical trials included in this analysis did
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190not use a standard deﬁnition for statin-associated
myalgia, and only 1 trial speciﬁcally queried patients
regarding muscle problems.
Until large clinical trials incorporate uniform deﬁ-
nitions and standardized assessment of myalgias,
the incidence and prevalence of statin-induced my-
algias remains uncertain. Furthermore, pre-statin
assessments of myopathy, myalgias, and other
constitutional symptoms, such as fatigue, should be
performed to ensure that symptoms present at base-
line are not erroneously attributed to statin therapy.
Notwithstanding these controversies, simple strate-
gies to overcome intolerance to statins have been
successful. Rechallenging with the same or a different
statin, reduced dosing, or alternate-day dosing have
proven effective for 92.2% of patients who were
initially intolerant of statins (46).
Misperceptions regarding the long-term safety
and risk-beneﬁt ratio of lipid lowering may also
contribute to nonadherence. Although statins can
increase the incidence of diabetes mellitus (1 addi-
tional case per 500 patients treated with intensive vs.
moderate-intensity statin therapy), existing data
suggests that the CVD beneﬁts outweigh this risk (47).
Patient counseling on these beneﬁts and pre-
emptively addressing concerns regarding adverse ef-
fects are important measures to improve adherence.
PILL BURDEN AND
FIXED-DOSE COMBINATION THERAPY
Guideline-recommended therapy for patients after
ACS speciﬁes the use of multiple agents, including a
statin, aspirin, and often an (angiotensin-converting
enzyme) inhibitor and beta-blocker. Although cost
may affect adherence, in the MI-FREEE (Post-
Myocardial Infarction Free Rx Event and Economic
Evaluation) trial (48), elimination of copayments
resulted in only a 4% to 6% improvement in adher-
ence. Overall rates of adherence to prescribed treat-
ment were <50% (even in the group with full
coverage) at a median follow-up of 394 days. There-
fore, other factors, including pill burden, may have a
greater effect on nonadherence than cost.
Adherence to medication is inversely related to the
number of pills and doses required per day (21).
Reduction of pill burden has demonstrated improve-
ment in adherence, particularly in patients at high
risk for CVD (20,49). Fixed-dose combination therapy
(FDC), or the polypill, contains medications that
address multiple CVD risk factors and is gaining mo-
mentum for its potential to facilitate application of
guideline-recommended therapy (20). The polypill is
now under investigation as a measure to improveadherence and outcomes in secondary prevention of
CVD.
In the UMPIRE (Effects of a Fixed Dose Combina-
tion Strategy on Adherence and Risk Factors in Pa-
tients with or at High Risk of CVD) trial (49), use of a
pill combining simvastatin with aspirin, lisinopril,
and atenolol demonstrated a substantial improve-
ment in self-reported adherence compared with usual
care (86% in the FDC arm vs. 65% in the usual-care
arm; p < 0.001). Among patients nonadherent
before study enrollment, a marked improvement in
adherence was noted (77.2% in the FDC arm vs. 23.1%
in the standard-care arm; p < 0.01).
Most recently, the FOCUS (Fixed-Dose COmbina-
tion Drug for Secondary Prevention PROJECT) trial
(50) tested adherence to the polypill versus its 3
individual components (simvastatin 40 mg, aspirin
100 mg, and ramipril 2.5, 5, or 10 mg) in a randomly
selected population of 695 patients from 4 countries
following acute MI as part of phase 2 testing. After
9 months of follow-up, the polypill group demon-
strated improved adherence compared with the
group receiving 3 separate medications (50.8%
compared with 41%; p ¼ 0.019) without an increase
in adverse effects, demonstrating the potential
utility of this strategy in secondary prevention.
Notably, the study was not designed to assess
clinical outcomes.
From a global health perspective, the polypill’s
potential to improve CVD event reduction in sec-
ondary prevention is appealing for patients in
Western nations due to reduced complexity of
treatment, convenience, and ease of distribution. In
lower-income countries, where CVD is projected to
constitute the leading cause of death by 2030, its
potential to deliver medications at lower cost is
particularly appealing (20). Detractors express con-
cerns regarding efﬁcacy and the possibility that side
effects from 1 component could lead to discontin-
uation of treatment and loss of beneﬁt from all
drugs in the formulation. Therefore, caution is
warranted, and larger clinical outcomes trials are
needed.
CONCLUSIONS AND OUTLOOK:
THE PRESENT AND FUTURE
Despite great advances in optimizing medical man-
agement after ACS, fundamental challenges to
achieving cardiovascular risk reduction remain.
Within the optimal conditions of recent clinical trials,
patients continue to demonstrate high rates of non-
adherence after ACS. Multiple large database regis-
tries report even greater rates of nonadherence and
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191underutilization of high-intensity statin therapy.
These failures have an enormous effect on achieving
improved outcomes.
Guidelines, enhanced quality metrics, coordina-
tion of care, and outpatient outreach programs offer
mechanisms to improve implementation of system-
based approaches to optimal prescribing. Strategies
that incorporate strong clinical care partnerships
to address nonadherence to smoking cessation, hy-
pertension control, exercise programs, and lipid
management will result in improved outcomes after
ACS. The polypill is a strategy that offers a viable,
simple, and highly effective intervention to over-
come nonadherence to antiplatelet, lipid, and bloodpressure medication use in high-risk patients.
Although a well-designed clinical outcomes trial
supports combination therapy with a statin plus
ezetimibe to reduce CVD events in ACS patients,
increasing provider awareness of guideline-driven
high-intensity statin utilization and patient adher-
ence to all forms of therapy may be more important
ways to improve clinical outcomes.
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